SOURCE: G2 Intelligence

G2 Intelligence

September 09, 2011 13:23 ET

Clinical Labs and Pathology Groups Meet to Address the Rapidly Evolving Area of Molecular Testing in Oncology

G2 Intelligence's Molecular Diagnostics for Cancer Conference Comes to San Francisco, September 23rd

PETERBOROUGH, NH--(Marketwire - Sep 9, 2011) - As molecular testing and genetic analysis continue to transform laboratory medicine, oncology is the area in which many of these novel diagnostics have the most powerful and attractive applications. From superior detection of the virus that causes cervical cancer to correlating gene expression with cancer drug metabolism and response, molecular testing is creating unprecedented opportunities to personalize patient care and expand the reach of diagnostics across the healthcare continuum.

Questions continue to arise in this rapidly changing area of molecular diagnostics: how best to configure organizations and systems to deliver truly personalized care, how to navigate the complex reimbursement system, what role next-generation sequencing will play in molecular diagnostics, and foremost in the minds of business leaders in "Oncological MDx," what clinical opportunities these burgeoning services represent.

To address these and other critical issues, G2 Intelligence, the leading market intelligence firm in diagnostics, announces a conference on molecular diagnostics focused entirely on cancer testing. Taking place September 23, 2011, at the W Hotel in San Francisco, the one-day event will provide a broad range of clinical labs with practical, innovative, and proven tools and strategies to succeed in this fast-growing area.

Professionals from across the spectrum of laboratory medicine will weigh in on the future of molecular diagnostics for cancer from a variety of perspectives.

"All eyes are on oncology. It's a real proving ground for molecular testing," says Stephanie Murg, managing director of G2 Intelligence, "And, as health care reform, personalized medicine, FDA regulation, and reimbursement pressures continue to reshape the diagnostics landscape, clinical laboratories and pathology groups need to adapt."

With that in mind, the agenda explores key opportunities around such topics as:

  • Delivering on the Promise of Personalized Medicine
  • Companion Diagnostics for Targeted Cancer Therapies: Current Trends and Future Directions
  • Molecular Diagnostics at MD Anderson Cancer Center
  • Minimizing Risk: Quality Control in Molecular Diagnostics
  • Next Generation Diagnostics: Uniting Lab Services and Products

Distinguished faculty in attendance to include:

  • Gyorgy Abel, M.D., Ph.D., Director, Clinical Immunology and Molecular Diagnostics/Clinical Chemistry, Department of Laboratory Medicine, Lahey Clinic
  • Paul R. Billings, M.D., Ph.D., Chief Medical Officer, Life Technologies
  • Mark E. Erwin, Senior Director, Reimbursement & Government Affairs Prometheus Therapeutics & Diagnostics
  • William Manion, MBA, M.D., Ph.D., JD, Chairman, Department of Pathology, and Laboratory Director, Memorial Hospital of Salem County and Memorial Hospital of Burlington County; President and CEO, Diagnostic Pathology Consultants
  • Mark Reynolds, Ph.D., Senior Director, New Product Development, Companion Diagnostics and New Technology, Gen-Probe
  • Clark A. Rundell, Ph.D. DABCC, Vice President of Research and Co-founder, Maine Molecular Quality Controls
  • Shawn Becker, M.D., Vice President, Marketing and Reimbursement, Pathwork

G2 also hosts the annual spring Molecular Diagnostics conference in Boston. Now in its seventh year, it is recognized as the preeminent gathering of molecular and genetics experts and business leaders representing the nation's top molecular laboratories.

To find out more, or to register for the fall 2011 Molecular Diagnostics for Cancer event, visit www.mdxconference.com or call 1.800.401.5937. Group discounts are available for three or more people from the same organization. For group registrations, please call Jeff Watkins at 973.718.4709 to facilitate your registration, or email jwatkins@G2Intelligence.com.

About G2 Intelligence

Advancing the Business of Diagnostic Medicine

G2 Intelligence provides timely, accurate, and trusted analysis of industry and market trends, legal and regulatory developments, and technology and innovation that directly affect the operations, financial performance, and competitive position of diagnostic testing laboratories and related medical services providers.

Formerly known as "Washington G-2 Reports," the company has covered and reported on the diagnostic industry for over 30 years. G2 Intelligence delivers topical and analytical periodicals, proprietary research studies, and custom advisory services, and through live and virtual events, facilitates industry meetings and information exchanges.

The mission of G2 is to deliver relevant, meaningful, and actionable findings on diagnostic industry markets, related regulatory changes, and lab operations.

G2 Intelligence is a division of Kennedy Information, LLC a leading provider of professional markets analysis.

More information is available for you at www.G2Intelligence.com.

Contact Information

  • Contact:
    Dan Houder
    COO and Publisher
    G2 Intelligence
    Email Contact